Research
Kristen Brantley, Ph.D., a new Susan G. Komen® research investigator at Dana-Farber Cancer Institute, is hoping to reveal some of the underlying biological factors that lead to worse breast cancer outcomes and survival for young women. Breast cancer among young women is an increasing concern in the U.S., with the most recent report from the […]
Every year, the San Antonio Breast Cancer Symposium (SABCS) brings together thousands of doctors, researchers and patient advocates to discuss the latest, practice-changing advances in breast cancer research and care. SABCS 2024 was no exception. At this year’s symposium, new research was announced that has the potential to change clinical practice for a wide range […]
Susan G. Komen recently honored five exceptional individuals for their transformative contributions to breast cancer research, treatment and advocacy. The Brinker Awards, Rising Star Researcher Award and Research Advocacy Champion Award are some of Komen’s highest honors in research, recognizing leaders who are advancing efforts to save lives and improve patient outcomes. Established in 1992, […]
This week, the San Antonio Breast Cancer Symposium (SABCS) is convening nearly 11,000 doctors, researchers and patient advocates to discuss the latest advances in breast cancer research. Susan G. Komen is showcasing its 360-degree approach to tackling breast cancer in four presentations at this year’s conference. Improving Patient Navigation Services for those with Metastatic Breast […]
People who are living with metastatic breast cancer (MBC) face many challenges, and where the cancer has spread can greatly impact a person’s experience. Breast cancer that has spread (metastasized) to the brain is no exception. In this next episode of Breast Cancer Breakthroughs, brought to you in collaboration with the American Brain Tumor Association, […]
The outlook for people with HER2-positive (HER2+) metastatic breast cancer (MBC) has improved significantly over the past decades thanks to recent advancements in research, including the development of HER2-targeted therapies. While these treatments do extend the life of many patients, they can also bring adverse side effects, high costs and the inconvenience of regular visits […]
Breast cancer is smart, and often finds ways to adapt and survive, even with targeted therapies. This makes treatment challenging, especially for metastatic or aggressive breast cancers like triple negative breast cancer (TNBC). In response to this challenge, researchers are seeking new ways to improve treatment outcomes for women with TNBC. TNBC is an aggressive, […]
For decades, breast cancer research has long been limited by the lack of diversity in data. Each person’s breast cancer experience tells their own story and is one piece of the puzzle of finding the cures for breast cancer. This is one of the reasons why Susan G. Komen’s ShareForCures® research registry was created. This […]
Breast cancer is often thought of as a disease that primarily affects women, but men also have a small amount of breast tissue, which means they can get breast cancer too. In the U.S., approximately one in every 100 breast cancer cases is diagnosed in a man. An estimated 2,790 men in the U.S. will […]
Research shows there are many risk factors for breast cancer. These risk factors can be related to biology, lifestyle, genetics and more. While being born female and getting older both increase your risk for breast cancer, other factors may reduce your risk. Adding exercise into your routine or limiting alcohol intake are two lifestyle choices […]
Research has shown that exercise can improve overall survival, treatment tolerability and quality of life for women with early-stage breast cancer. But what about women who are living with metastatic breast cancer (MBC)? Through a clinical trial, researchers are exploring whether the addition of exercise to standard treatment could hold promise for women living with […]
For the past 20 years, people with early estrogen receptor-positive (ER+) breast cancer have received a standard treatment, including hormone therapies like aromatase inhibitors or tamoxifen. While these patients generally have good outcomes after this treatment, they are still at risk for recurrence. As researchers seek more targeted and effective treatments for people with early […]
